If You Invested $1,000 in Vir Biotechnology, Inc. (VIR)
This article analyzes the historical stock performance of Vir Biotechnology, Inc. (VIR). It calculates the returns on hypothetical $1,000 investments made one and five years ago, showing disparate outcomes. The article also provides an overview of Vir Biotechnology's focus on infectious diseases and oncology, its clinical programs, and strategic collaborations.
Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA significantly increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10,878.9% in Q1, now owning 1.48 million shares worth $13.3 million. This increase comes despite Vir Biotechnology reporting weaker than expected quarterly results and analysts projecting a full-year EPS loss of $1.81. Wall Street maintains a "Moderate Buy" rating with an average price target of $20.88, though some analysts have downgraded the stock and company insiders have sold shares.
VIR - Vir Biotechnology Inc Latest SEC Filings
This page provides an overview of Vir Biotechnology Inc (VIR) focusing on its latest SEC filings and comprehensive financial data. It includes key stock performance metrics, valuation ratios, and insider/institutional ownership percentages, alongside recent earnings figures and analyst recommendations.
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology, a clinical-stage biopharmaceutical company, announced its intention to offer $200,000,000 of common stock in an underwritten public offering. The company will also grant underwriters a 30-day option to purchase an additional $30,000,000 of shares. The offering is subject to market and other conditions, and there's no assurance as to its completion, size, or terms.
Form 144 Vir Biotechnology For: 29 June By Investing.com
This article from Investing.com reports on a Form 144 filing by Vir Biotechnology for June 29. It includes the stock symbol VIR and its performance on that date, amidst various market data and other news. The content primarily serves as a placeholder for the filing information, augmented by general financial market metrics.
OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR
OP Asset Management Ltd has acquired a new position in Vir Biotechnology, purchasing 113,028 shares valued at approximately $1.013 million in the first quarter of 2026. This move comes as institutional investors now own 65.32% of the company's shares. Despite a recent weak quarter with a larger-than-expected loss and no revenue, analysts maintain a "Moderate Buy" rating with an average target price of $20.88.
Form 144 Vir Biotechnology For: 29 June By Investing.com
This article announces the filing of Form 144 for Vir Biotechnology on June 29th, as reported by Investing.com. It is a very brief news item, primarily serving as an update on a financial filing for the company. The article contains minimal descriptive text and primarily lists various market data and other news headlines.
[144] Vir Biotechnology, Inc. SEC Filing
This article reports on Vir Biotechnology, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the sale of 16,000 shares of common stock acquired through a stock option exercise, with an aggregate market value of $165,138.95, and mentions Fidelity Brokerage Services LLC as the broker. The document also provides a snapshot of the company's recent news, SEC filings, and stock data.
Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR
This article provides financial information for Vir Biotechnology, Inc. (NASDAQ: VIR), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data point or a report generated by TradingView, detailing a specific period's value, change, and percentage change for this metric.
VIR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Vir Biotechnology, Inc. (VIR) stock, including analyst price targets, current stock performance, and financial data. It highlights that the 9 analysts have a price target of 21.56 USD with a maximum estimate of 30.00 USD and a minimum of 16.00 USD. The company's stock has shown significant increases over the last year, despite recent negative earnings surprises.
Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR
This article focuses on the enterprise value to EBIT forward metric for Vir Biotechnology, Inc. (NASDAQ: VIR). It directly presents the financial data for this specific metric without further analysis or commentary within the provided content. The details are presented in a straightforward, data-centric format.
VIR: Hepatitis Delta Program And Oncology Partnership Will Drive Future Upside
Analysts have increased their average price target for Vir Biotechnology to $21.56, up from $20.67, driven by an improved revenue growth outlook and a higher future P/E assumption, factoring in the potential of emerging hepatitis delta virus therapies. The company is advancing in its oncology pipeline with VIR-5500 for prostate cancer and will present key data for its hepatitis delta combination therapy at EASL Congress 2026. Despite a legal dispute with Brii Biosciences, Vir Biotechnology has secured a significant collaboration and licensing agreement with Astellas for VIR-5500, including a substantial upfront payment and future milestones.
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk
Vir Biotechnology Inc (VIR) has a current risk assessment score of 4.70, placing it 67th out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.66 indicates higher volatility compared to the S&P 500. The report details various risk metrics including volatility, maximum drawdown, and return-to-drawdown ratios over different periods.
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Vir Biotechnology Inc (VIR), giving it a current financial score of 7.47, ranking it 116 out of 389 in its industry. The company shows stable financial status and high operating efficiency. However, its latest quarterly revenue decreased by 100.96% year-over-year, and net profit decreased by 3.91%.
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 1-year price target of $20.88. Recent analyst updates were largely positive, including increased price targets from several firms, though Weiss Ratings maintained a "sell" rating. The company reported a weak quarterly earnings miss, ongoing losses, and notable insider selling activity despite the generally positive analyst outlook.
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Vir Biotechnology Inc (VIR), noting that relevant data for business segments, regional revenue, and profit contribution for FY2025 has not yet been disclosed by the company. It indicates that the United States contributed $68.56 million in revenue, though the proportion is listed as 0.00%. The report includes current stock quotes and market capitalization for VIR.
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants
Vir Biotechnology director Timothy Coughlin has been granted restricted stock units (RSUs) and stock options. He received two RSU awards of 8,000 shares each and two stock option grants covering 16,000 shares each, with an exercise price of $8.51 per share, expiring in 2036. These grants, reported in a Form 4 SEC filing, have various vesting schedules, with initial vesting beginning on June 9, 2027.
Vir Biotechnology (VIR) director Coughlin reports zero share ownership
Vir Biotechnology director Timothy Coughlin filed an initial Form 3, reporting zero beneficial ownership of the company's common stock as of June 9, 2026. This SEC filing establishes his initial position as an insider, showing no direct holdings. A Form 3 is required when an individual becomes an officer, director, or large shareholder to disclose their initial securities ownership.
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00
Morgan Stanley has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $27.00 from $23.00, maintaining an "overweight" rating. This adjustment suggests a potential upside of 227.27% from the current stock price. Despite weak recent earnings, insider selling, and mixed analyst opinions, the stock holds a "Moderate Buy" consensus rating with an average target of $20.88.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Mr. Coughlin, former CFO of Neurocrine Biosciences, Inc., brings extensive financial and operational experience across the biopharmaceutical industry. His expertise will be valuable as Vir Biotechnology advances its portfolio of treatments for serious infectious diseases and cancer.
Vir Biotechnology appoints Timothy Coughlin to board
Vir Biotechnology (NASDAQ:VIR) has announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin brings extensive financial and biotechnology experience, having previously served as CFO of Neurocrine Biosciences and holding various board positions. This appointment comes as Vir navigates a growth phase with a strong cash position but ongoing cash burn from clinical programs, and follows recent financial shortfalls and upcoming presentation of Phase 2 trial data.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Coughlin, former CFO of Neurocrine Biosciences, brings extensive experience in finance and strategic development from his roles in a fully integrated commercial pharmaceutical company and various other boards. His expertise is expected to be highly valuable as Vir Biotechnology advances its portfolio in infectious diseases and cancer.
[8-K] Vir Biotechnology, Inc. Reports Material Event
Vir Biotechnology, Inc. has announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the board size from seven to eight members. Coughlin will serve as a Class III director until the 2028 annual meeting and has also been appointed Chair of the Audit Committee. He will receive standard non-employee director compensation, including stock options and restricted stock units, and there are no disclosed related party transactions.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) has announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Coughlin, former CFO of Neurocrine Biosciences, brings extensive experience in finance and biotechnology leadership. He is expected to contribute to the company's advancement of treatments for hepatitis delta and its pipeline of T-cell engagers.
WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR
WINTON GROUP Ltd significantly increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing an additional 131,555 shares, bringing its total holding to 189,306 shares valued at approximately $1.14 million. This increased ownership comes despite Vir Biotechnology reporting a larger-than-expected quarterly loss and lower revenue than anticipated. Analysts, however, maintain a "Moderate Buy" consensus rating for the stock with an average price target of $20.38.
VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR)
This article provides recent news and analysis for VIR Biotechnology Inc. (NASDAQ:VIR), including its stock price, recent appointments to its Board of Directors, upcoming clinical trial data presentations, and a report on its Q4 2025 revenue. The company is highlighted as a high-growth momentum pick.
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
The article summarizes a bullish thesis on Vir Biotechnology, Inc. (VIR) from Valueinvestorsclub.com, highlighting its lead asset VIR-5500 for metastatic castration-resistant prostate cancer. The therapy shows promising Phase 1 data with high response rates and reduced toxicity, reinforced by a strategic collaboration with Astellas Pharma. Despite not being a top hedge fund pick, the company's valuation and potential acquisition make it an attractive prospect, though the author's conviction leans more towards AI stocks for higher short-term returns.
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership
Vir Biotechnology Inc. (VIR) saw its stock surge by 60% pre-market after strong fourth-quarter earnings, positive Phase 1 cancer therapy data for VIR-5500, and a new partnership with Astellas Pharma. Analysts responded with upgrades and increased price targets, signaling strong confidence in the company's prostate cancer treatment and financial outlook. The collaboration with Astellas includes significant upfront payments and potential milestones, bolstering Vir's development and commercialization capabilities.
Insider Sell: Janet Napolitano Sells 3,200 Shares of Vir Biotech
Janet Napolitano, a Director at Vir Biotechnology Inc (VIR), sold 3,200 shares of the company on June 1, 2026. This transaction reduces her total holdings to 21,216 shares. The company's stock was trading at $9.45, valuing it as a "Possible Value Trap, Think Twice" based on its GuruFocus Value of $17.89.
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I
Brent Sabatini, Senior Vice President and Chief Accounting Officer at Vir Biotechnology Inc (VIR), sold 379 shares of the company on June 1, 2026. This transaction follows a pattern of insider selling, with 41 insider sells and no buys over the past year. Vir Biotechnology Inc's stock was trading at $9.45, suggesting it might be a "Possible Value Trap" according to GuruFocus's GF Value of $17.89.
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00
Leerink Partners has raised its price target for Vir Biotechnology (NASDAQ:VIR) to $21.00 from $20.00, maintaining an "outperform" rating, which suggests a significant upside of 137.02% from its prior closing. Despite this, the company's recent quarterly results were weak, with revenue and EPS missing analyst estimates, and insiders have been selling shares. The stock traded up 1.4% to $8.86, and analyst consensus remains a "Moderate Buy" with an average target of $20.38.
Vir Biotechnology director Janet Napolitano sells $30,239 in stock
Janet Napolitano, a director at Vir Biotechnology (NASDAQ:VIR), sold 3,200 shares of company stock for $30,239 on June 1, 2026, as part of a pre-arranged trading plan. This sale occurred despite the stock's 72% return over the past year, with shares currently trading below her sale price. The company recently reported disappointing Q1 2026 earnings, missing both EPS and revenue expectations, and is scheduled to present data from its Phase 2 SOLSTICE trial at the EASL Congress 2026.
Vir Biotechnology director Janet Napolitano sells $30,239 in stock
Janet Napolitano, a director at Vir Biotechnology (NASDAQ:VIR), sold 3,200 shares worth $30,239 on June 1, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred despite the stock's 72% return over the past year, with shares trading below the director's sale price and analysis suggesting the company is overvalued. The company also recently reported a significant Q1 2026 earnings and revenue shortfall but is set to present Phase 2 trial data at EASL Congress 2026.
Vir Biotechnology (VIR) SVP sells 379 shares in pre-planned trade
Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology (VIR), reported the sale of 379 shares of common stock at $9.45 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025. After the sale, Sabatini directly holds 61,902 shares, and the sold shares were originally acquired through an employee stock purchase program.
VIR (NASDAQ: VIR) Form 144 lists 379 ESPP shares; insider sold 7,711
Vir Biotechnology, Inc. (NASDAQ: VIR) filed a Form 144 notice revealing a proposed sale of Common Stock. This filing details an ESPP purchase of 379 shares on May 29, 2026, and also notes a previous sale of 7,711 shares by Brent Sabatini on March 23, 2026, for a value of $70,324.32. The broker involved in these transactions is Fidelity Brokerage Services LLC, with the filing date being June 1, 2026.
[144] Vir Biotechnology, Inc. SEC Filing
This SEC filing (Form 144) for Vir Biotechnology, Inc. details a proposed sale of 3200 shares of common stock with an aggregate market value of $30,240.00. The shares were acquired through restricted stock vesting on May 30, 2026, and are intended to be sold on NASDAQ on June 1, 2026, through Fidelity Brokerage Services LLC. The filing indicates a neutral impact and sentiment.
Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions
Vir Biotechnology (NASDAQ:VIR) is forecast to grow earnings and revenue by 21.7% and 19.5% per annum, respectively, though it is expected to remain unprofitable for the next three years. Recent updates highlight significant advancements in its chronic hepatitis delta (CHD) and oncology programs, including positive Phase 2 data for CHD and progress in Phase 1 trials for metastatic prostate cancer. Despite analyst optimism and strategic partnerships like the one with Astellas, the company faces risks such as negative free cash flow, shareholder dilution, and volatile share price, along with concerns about insider selling.
Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option
Vir Biotechnology director Ramy Farid received 8,000 Restricted Stock Units (RSUs) and a stock option for 16,000 shares at an exercise price of $9.10 per share. These equity compensation awards are part of the company's incentive plan and are scheduled to vest in full on May 27, 2027. Following the RSU grant, Farid directly holds 32,000 shares of common stock, in addition to the newly granted stock option.
Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options
Jeffrey S. Hatfield, a director at Vir Biotechnology (VIR), was granted 8,000 restricted stock units (RSUs) and 16,000 stock options as compensation. Both awards will fully vest on May 27, 2027, with the stock options having an exercise price of $9.10 per share and expiring on May 26, 2036. Following these grants, Hatfield directly holds 39,806 shares of common stock.
Vir Biotechnology (VIR) director receives RSU and stock option grants
Vir Biotechnology director Charles Elliott Sigal was granted 8,000 restricted stock units (RSUs) and stock options for 16,000 shares, with an exercise price of $9.10 per share. Both the RSUs and stock options are set to vest on May 27, 2027. Following these grants, Sigal directly holds 39,806 shares of common stock and indirectly holds an additional 10,000 shares through Sigal Family Investments, LLC.
Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option
Vir Biotechnology director Robert J. More received 8,000 restricted stock units (RSUs) and a stock option for 16,000 shares. Both equity awards will vest in full on May 27, 2027, with the stock option having an exercise price of $9.10 per share and expiring on May 26, 2036. Following these transactions, More directly holds 48,656 shares of common stock and 16,000 option shares.
Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options
Vir Biotechnology director Janet Napolitano was granted 8,000 restricted stock units (RSUs) and 16,000 stock options as part of her compensation. Both the RSUs and stock options will vest in full on May 27, 2027, with the options having an exercise price of $9.10 per share. Following these grants, Napolitano directly holds 24,416 shares of common stock and 16,000 stock options in the company.
Vir Biotechnology, Inc. Announces Changes in Board and Audit Committee, Effective May 26, 2026
Vir Biotechnology, Inc. has announced changes to its Board of Directors and Audit Committee. Saira Ramasastry, a board member and Chair of the Audit Committee, stepped down effective May 26, 2026, due to a business conflict. Robert More, MBA, has been appointed as the new Chair of the Audit Committee, and the Board's size has been reduced from eight to seven members.
Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes
Vir Biotechnology announced that director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, due to a business conflict, with Robert More appointed as the new Chair. The company also disclosed the results of its 2026 Annual Meeting, where stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as its independent registered public accounting firm. The Board size was reduced from eight to seven members following Ramasastry's departure.
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $20.25. Despite recent analyst upgrades and target hikes, the company reported a significant quarterly loss, missing both EPS and revenue estimates. Insider selling has also occurred, with shares trading significantly below the average analyst target.
How Marianne De Backer saved Vir Biotechnology after flu drug failure
Marianne De Backer, CEO of Vir Biotechnology since 2023, has revitalized the company after a flu drug failure. She achieved this by closing three sites, laying off over a third of the workforce, and securing multi-million dollar licensing deals.
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com
Vir Biotechnology Inc. (NASDAQ:VIR) will present Phase 2 SOLSTICE trial data for its hepatitis delta treatments, tobevibart and elebsiran, at the EASL Congress 2026 in Barcelona. The presentation will cover Week 96 efficacy and safety results for combination therapy, with a separate poster on the impact of BMI on ALT normalization. Despite significant stock returns, InvestingPro analysis suggests the stock is currently overvalued, and the company recently reported a substantial miss on Q1 2026 earnings expectations.
Vir Biotechnology to present hepatitis delta trial data at EASL
Vir Biotechnology (NASDAQ:VIR) is set to present Phase 2 SOLSTICE trial data for its chronic hepatitis delta treatments, tobevibart and elebsiran, at the EASL Congress 2026. The presentation will cover Week 96 endpoint results and Week 48 subgroup data, highlighting the efficacy and safety of the treatments. Despite a 91% return over the past year, the company recently reported a significant Q1 2026 earnings and revenue shortfall, and its stock is considered overvalued according to InvestingPro.
New hepatitis delta drug combo data lands ‘Best of EASL 2026’ slot
Vir Biotechnology announced it will present complete Week 96 data from its Phase 2 SOLSTICE trial for chronic hepatitis delta at the EASL Congress 2026. The key oral presentation, showing results for tobevibart and elebsiran, was selected for inclusion in "Best of EASL 2026," while a poster presentation will detail subgroup analysis on how BMI impacts ALT normalization. This combination therapy aims to disrupt the hepatitis delta virus life cycle at multiple points.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
SB Investment Advisers (UK) Ltd significantly reduced its stake in Vir Biotechnology by selling over 2.1 million shares worth an estimated $17.28 million, despite the stock nearly doubling in the past year. This move is seen as portfolio management rather than a complete withdrawal, as Vir Biotechnology remains a notable holding for SB Investment Advisers. The company is focusing on evolving beyond its pandemic-era identity, with advancements in its oncology and hepatitis delta programs.
